Cumberland Pharmaceuticals Files 8-K

TL;DR

CPRX filed an 8-K, something happened but they aren't saying what yet.

AI Summary

Cumberland Pharmaceuticals Inc. filed an 8-K on November 4, 2024, to report other events. The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.

Why It Matters

This filing indicates a material event has occurred for Cumberland Pharmaceuticals Inc., requiring disclosure to investors, though the specific nature of the event is not detailed in the provided text.

Risk Assessment

Risk Level: medium — The filing of an 8-K often signifies significant corporate events, but the lack of specific details in this excerpt makes it difficult to assess the precise risk.

Key Players & Entities

• CUMBERLAND PHARMACEUTICALS INC (company) — Registrant
• November 4, 2024 (date) — Filing Date

FAQ

Filing Documents

• cpix-20241104.htm (8-K) — 28KB
• 0001628280-24-045054.txt ( ) — 150KB
• cpix-20241104.xsd (EX-101.SCH) — 2KB
• cpix-20241104_lab.xml (EX-101.LAB) — 21KB
• cpix-20241104_pre.xml (EX-101.PRE) — 12KB
• cpix-20241104_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events I n April 2023, we announced that we expected that our Caldolor product would be eligible for separate Medicare reimbursement under the Non-Opioids Prevent Addiction in the Nation Act (the "NOPAIN Act"), which was enacted as part of the Consolidated Appropriations Act of 2023. This Act requires the Centers for Medicare & Medicaid Services ("CMS") to provide separate reimbursement for non-opioid products that are used to manage pain during surgeries conducted in hospital outpatient departments or in ambulatory surgical centers. The NOPAIN Act applies, in part, to products that are indicated to provide analgesia without acting upon the body's opioid receptors. The reimbursement for non-opioid pain alternatives under the NOPAIN Act will apply to those products that are furnished between January 1, 2025, and January 1, 2028. Cumberland submitted comments to CMS in July 2023 and July 2024, arguing, among other things, that Caldolor meets the statutory requirements for separate payment under the NOPAIN Act because the U.S. Food and Drug Administration ("FDA") approved Caldolor for a general acute pain indication that encompasses use for the reduction of postoperative pain based on clinical studies in patients with postoperative pain. On November 1, 2024, CMS announced a list of products for separate payment under the NOPAIN Act through their Calendar Year 2025 Medicare Outpatient Prospective Payment System ("OPPS") Ruling. The list does not include Caldolor. CMS concluded that Caldolor and certain other products do not qualify for separate payment under the NOPAIN Act because "there is no mention of post-operative or post-surgical use in the FDA-approved indications." The Company was surprised and disappointed with this determination, as the majority of Caldolor's use is associated with surgery and the FDA approval of the product's pain indication was based on studies of patients with post-surgical pain. Furthermore, CMS's November 1 list of p

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS: This press release contains forward-looking statements, which are subject to certain risks and reflect the companies' current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of the companies' operations are subject to factors outside of its control, and any one or combination of these factors could materially affect results of operations. There can be no assurance that anticipated results associated with the brand will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The companies do not undertake any obligation to publicly revise these statements to reflect events after the date hereof. Investors should refer to filings with the government securities agencies for more information, including the risk factors associated an investment in each company.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cumberland Pharmaceuticals Inc. Dated: November 4, 2024 By: /s/ John Hamm John Hamm Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR